During Life Sciences Week’s celebration of Alberta’s health sector, an Edmonton Region-based company, Nanostics, announced their prostate cancer diagnostic tool will now be made available in the U.S. and Middle East — only a year after the test first launched in Canada.
Nanostics ClarityDX (CDX) Prostate leverages biological data, clinical information, and AI-driven models to calculate a risk score for aggressive prostate cancer, drastically improving screening procedures and reducing the number of unnecessary biopsies. The tool offers valuable support to men and their healthcare providers, helping them make more informed decisions about whether to pursue an invasive biopsy after an elevated prostate-specific antigen (PSA) test or an abnormal digital rectal exam (DRE).
Since ClarityDX Prostate relies on PSA blood test and patient clinical data, it can be easily integrated into the healthcare process with minimal patient inconvenience and low cost to the healthcare system.
Since its launch during 2023’s Life Sciences Week, ClarityDX Prostate is already available across most of Canada, but Nanostics has now partnered with two companies to make the test available in international markets .
“We want all men to benefit from early detection leading to better outcomes,” Dr. John Lewis, CEO of Nanostics and Bird Dogs Chair of Translational Oncology at the University of Alberta, said.
“We can now provide CDX Prostate to [more] men … so they can find out their risk of having aggressive prostate cancer,” Dr.Lewis said. “This test gives men and their doctors more accurate information to make better informed decisions about biopsy and treatment plans.”
The team at Nanostics is working with Protein BioDiagnostics in Florida to expand the CDX Prostate tool to the U.S. and Calgary’s Oncohelix to bring this tool to the Middle East.
About one in every eight men will be diagnosed with prostate cancer, making it the second most common cancer in the U.S.
Prostate cancer’s prevalence underscores the critical need for innovative screening solutions, especially as global healthcare demands continue to grow.
The Edmonton Region has become a hub for such medical advancements, with the University of Alberta driving cutting-edge research.
With their expansion to the middle east, Dr. Lewis said that Nanostics’ partnership with OncoHelix to bring the diagnostic tool “really shows how relevant Alberta-developed technology has become to the world.”
“Congratulations to the team at Nanostics on this expansion,” Malcolm Bruce, CEO of Edmonton Global, said.
“The Edmonton Region is quickly emerging as an exciting hub for the life science sector, more than 60% of Alberta’s life science companies are located here and the University of Alberta is globally ranked for their advancements in health research. Nanostics’ expansion of ClarityDX Prostate is yet another example of what’s possible for our life science sector.”
